Apixaban (eliquis) outperforms Rivaroxaban (xarelto) in venous thromboembolism bleeding risk

1. In the randomized COBRRA trial, apixaban was associated with substantially less clinically relevant bleeding than rivaroxaban in patients with acute venous thromboembolism.

2. The lower bleeding risk did not come at the cost of efficacy, as recurrent venous thromboembolism (VTE) rates were nearly identical between treatment groups.

A major comparative anticoagulation study has now provided some of the clearest direct evidence yet for clinicians managing acute venous thromboembolism. In the Phase 4 COBRRA trial, patients with newly diagnosed deep-vein thrombosis or pulmonary embolism were randomized to receive either apixaban or rivaroxaban for three months. Investigators found that clinically relevant bleeding occurred in 3.3% of patients assigned to apixaban, compared with 7.1% of those assigned to rivaroxaban. This translated into a striking reduction in bleeding risk during the most vulnerable initial treatment period. Importantly, the improvement in safety did not appear to reduce treatment effectiveness, since recurrent venous thromboembolism occurred at nearly identical rates in both groups. For practicing hematologists, hospitalists, cardiologists, and internists, these results support apixaban as a more favorable safer first-line option when bleeding risk is an important clinical concern. The difference may be related in part to rivaroxaban’s more intensive lead-in dosing strategy, which delivers higher anticoagulant exposure in the earliest phase of treatment. Although both medications are commonly grouped together as direct oral anticoagulants, these findings suggest they should not always be viewed as interchangeable. The study therefore adds meaningful practical guidance to a decision that often depends on habit, formulary preference, or convenience. Investigators also emphasized that real-world prescribing decisions should still take into account kidney function, adherence, insurance coverage, and patient-specific risk factors. Even so, this trial gives clinicians stronger evidence to individualize DOAC selection using comparative outcomes rather than assumptions. As future guidelines are updated, the COBRRA findings may help shift practice patterns toward apixaban in the acute VTE setting. The results also reinforce the broader principle that small differences within a drug class can translate into clinically meaningful differences for patients.

Image: PD

©2026 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.